Posay's Effaclar collection is the gold standard. Beloved for its lightweight textures, efficacious ingredients and friendly price point, it's no wonder the range is one of the brand's bestsellers. So ...

If you frequently experience facial redness, irritation and small bumps, you may be dealing with rosacea, a common skin condition that impacts more than 14 million people in the U.S. alone ...

The three sunscreens I tested out were Aldi’s Lacura SPF 30 Moisturising Sun Lotion (£2.79), E45 Sun Body Lotion 50+ (£14) and La Roche-Posay Anthelios UVMune 400 Invisible 50+ (£20).

All linked products are independently selected by our editors. If you purchase any of these products, we may earn a commission. But all this immense social media hype isn’t merely skin deep.

If you missed the last La Roche-Posay sale at Ulta, you’re in luck: Today, the brand’s popular SPF 50 sunscreen is on sale as part of Ulta’s Buy More Save More sale, with discounts on all ...

Pharmaceutical giant Roche may have made profits more than a hundred times what it cost the company to bring a rare-disease drug to the Indian market, The Times of India reported on April 28. The drug ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning the President Trump administration for an exemption. Roche is trying ...

Roche Holding AG reported a 6% growth in group sales for the first quarter of 2025, driven by an 8% increase in pharmaceutical sales. However, the company’s diagnostics sales remained flat ...

Roche says its imports into US offset by its US-made exports Says talking to various levels of Trump administration Company announced major investment in US on Tuesday April 24 (Reuters) - Swiss ...

FRANKFURT, April 24 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug ...